Rafael Coveñas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/324292/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Neurotensinergic System: A Target for Cancer Treatment. Current Medicinal Chemistry, 2022, 29, 3231-3260.	1.2	11
2	Regulation of Homeostasis by Neuropeptide Y: Involvement in Food Intake. Current Medicinal Chemistry, 2022, 29, 4026-4049.	1.2	6
3	The Neurokinin-1 Receptor Is Essential for the Viability of Human Glioma Cells: A Possible Target for Treating Glioblastoma. BioMed Research International, 2022, 2022, 1-13.	0.9	11
4	Involvement of the Orexinergic System in Feeding. Applied Sciences (Switzerland), 2022, 12, 86.	1.3	3
5	Why Use Aprepitant Only as a Cough Suppressant in Lung Cancer When at Higher Doses it Could Also Exert an Antitumor Action?. Archivos De Bronconeumologia, 2022, 58, 727-728.	0.4	6
6	Morphological Relationships between the Cholinergic and Somatostatin-28(1-12) Systems in the Alpaca (Lama pacos) Brainstem. , 2022, 1, 54-67.		2
7	Risk Genes in Schizophrenia and Their Importance in Choosing the Appropriate Antipsychotic Treatment. Current Pharmaceutical Design, 2021, 27, 3281-3292.	0.9	7
8	Neuropeptidergic Control of Feeding: Focus on the Galanin Family of Peptides. International Journal of Molecular Sciences, 2021, 22, 2544.	1.8	20
9	Neuroanatomical distribution of the enkephalinergic and tachykininergic systems in the alpaca brainstem: an immunohistochemical study. Folia Histochemica Et Cytobiologica, 2021, 59, 145-156.	0.6	0
10	Immunohistochemical study of the brainstem cholinergic system in the alpaca (Lama pacos) and colocalization with CGRP. European Journal of Histochemistry, 2021, 65, .	0.6	1
11	Mapping of folic acid in the children brainstem. Anatomy and Cell Biology, 2021, 54, 340-349.	0.5	1
12	The Novel Antipsychotic Drug Cariprazine and Cognition Enhancing Drugs: Indications for their Use as the Add-on Therapy in Schizophrenia. Current Pharmaceutical Design, 2021, 27, 4033-4038.	0.9	4
13	The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?. Cancers, 2020, 12, 2682.	1.7	52
14	Neurokinin receptor antagonism: a patent review (2014-present). Expert Opinion on Therapeutic Patents, 2020, 30, 527-539.	2.4	26
15	The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia. Journal of Clinical Medicine, 2020, 9, 1659.	1.0	23
16	The substance P and neurokinin-1 receptor system in human thyroid cancer: an immunohistochemical study. European Journal of Histochemistry, 2020, 64, .	0.6	12
17	Triple Negative Breast Cancer: How Neurokinin-1 Receptor Antagonists Could Be Used as a New Therapeutic Approach. Mini-Reviews in Medicinal Chemistry, 2020, 20, 408-417.	1.1	8
18	A close neuroanatomical relationship between the enkephalinergic (methionine-enkephalin) and tachykininergic (substance P) systems in the alpaca diencephalon. Folia Histochemica Et Cytobiologica, 2020, 58, 135-146.	0.6	1

#	Article	IF	CITATIONS
19	Enkephalins and ACTH in the mammalian nervous system. Vitamins and Hormones, 2019, 111, 147-193.	0.7	11
20	Antipruritic vs. Antitumour Action of Aprepitant: A Question of Dose. Acta Dermato-Venereologica, 2019, 99, 620-621.	0.6	12
21	Risperidone: A Commentary on Drug Profiling. Current Drug Discovery Technologies, 2019, 16, 315-316.	0.6	0
22	Neurokinin-1 Receptor Antagonists against Hepatoblastoma. Cancers, 2019, 11, 1258.	1.7	21
23	Galanin ($1\hat{a}\in$ 15)-fluoxetine interaction in the novel object recognition test. Involvement of 5-HT1A receptors in the prefrontal cortex of the rats. Neuropharmacology, 2019, 155, 104-112.	2.0	16
24	Neurokininâ€1 receptor antagonist aprepitant and radiotherapy, a successful combination therapy in a patient with lung cancer: A case report. Molecular and Clinical Oncology, 2019, 11, 50-54.	0.4	16
25	Neural Networks in Generalized Epilepsy and Novel Antiepileptic Drugs. Current Pharmaceutical Design, 2019, 25, 396-400.	0.9	15
26	Therapeutic Effect of Novel Antidepressant Drugs Acting at Specific Receptors of Neurotransmitters and Neuropeptides. Current Pharmaceutical Design, 2019, 25, 388-395.	0.9	4
27	Neurokinin-1 Receptor Antagonists as Anticancer Drugs. Letters in Drug Design and Discovery, 2019, 16, 1110-1129.	0.4	6
28	Glioma and Neurokinin-1 Receptor Antagonists: A New Therapeutic Approach. Anti-Cancer Agents in Medicinal Chemistry, 2019, 19, 92-100.	0.9	8
29	Comparison of Mono-dopaminergic and Multi-target Pharmacotherapies in Primary Parkinson Syndrome and Assessment Tools to Evaluate Motor and Non-motor Symptoms. Current Drug Therapy, 2019, 14, 124-134.	0.2	0
30	GEMALS: A promising therapy for amyotrophic lateral sclerosis. Experimental and Therapeutic Medicine, 2018, 15, 3203-3210.	0.8	2
31	Overexpression of kynurenic acid and 3-hydroxyanthranilic acid after rat traumatic brain injury. European Journal of Histochemistry, 2018, 62, .	0.6	10
32	Neurokinin-1 Receptor. , 2018, , 3437-3445.		4
33	Long-term Administration of Antipsychotic Drugs in Schizophrenia and Influence of Substance and Drug Abuse on the Disease Outcome. Current Drug Abuse Reviews, 2018, 10, 19-24.	3.4	11
34	Generation of specific antisera directed against D-amino acids: focus on the neuroanatomical distribution of D-glutamate and other D-amino acids. Folia Histochemica Et Cytobiologica, 2018, 55, 177-189.	0.6	5
35	Immunohistochemical mapping of neurotensin in the alpaca diencephalon. Folia Histochemica Et Cytobiologica, 2018, 56, 49-58.	0.6	2
36	Classical neurotransmitters and neuropeptides involved in generalized epilepsy in a multi-neurotransmitter system: How to improve the antiepileptic effect?. Epilepsy and Behavior, 2017, 71, 124-129.	0.9	36

#	Article	IF	CITATIONS
37	Mapping of enkephalins and adrenocorticotropic hormone in the squirrel monkey brainstem. Anatomical Science International, 2017, 92, 275-292.	0.5	6
38	Follow-up of multiple sclerosis patients treated with Endotherapia (GEMSP). Biomedical Reports, 2017, 6, 307-313.	0.9	2
39	Increased nuclear localization of substance P in human gastric tumor cells. Acta Histochemica, 2017, 119, 337-342.	0.9	10
40	The NK-1 receptor antagonist L-732,138 induces apoptosis in human gastrointestinal cancer cell lines. Pharmacological Reports, 2017, 69, 696-701.	1.5	17
41	Gemst: a taylor-made combination that reverts neuroanatomical changes in stroke. European Journal of Histochemistry, 2017, 61, 2790.	0.6	4
42	Targeting NPY, CRF/UCNs and NPS Neuropeptide Systems to Treat Alcohol Use Disorder (AUD). Current Medicinal Chemistry, 2017, 24, 2528-2558.	1.2	10
43	Detection of pantothenic acid-immunoreactive neurons in the rat lateral septal nucleus by a newly developed antibody. Folia Histochemica Et Cytobiologica, 2017, 54, 186-192.	0.6	4
44	Neurokinin-1 Receptor Antagonists in Lung Cancer Therapy. Letters in Drug Design and Discovery, 2017, 14, .	0.4	4
45	Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells. Journal of Neuro-Oncology, 2016, 126, 425-431.	1.4	35
46	Neurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: A new approach. Saudi Journal of Gastroenterology, 2016, 22, 260.	0.5	25
47	Mapping of somatostatinâ€28 (1â€12) in the alpaca (<scp><i>L</i></scp> <i>ama pacos</i>) brainstem. Microscopy Research and Technique, 2015, 78, 363-374.	1.2	3
48	New developments in the management of schizophrenia and bipolar disorder: potential use of cariprazine. Therapeutics and Clinical Risk Management, 2015, 11, 1657.	0.9	9
49	Targeting NK-1 Receptors to Prevent and Treat Pancreatic Cancer: a New Therapeutic Approach. Cancers, 2015, 7, 1215-1232.	1.7	13
50	The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs. Journal of Biosciences, 2015, 40, 441-463.	0.5	79
51	Classical Neurotransmitters and Neuropeptides Involved in Parkinson's Disease: Focus on Anti-Parkinsonian Drugs. Current Drug Therapy, 2015, 10, 66-81.	0.2	7
52	Lauryl-poly-L-lysine: A New Antimicrobial Agent?. Journal of Amino Acids, 2014, 2014, 1-10.	5.8	18
53	Uveal melanoma expresses NK-1 receptors and cyclosporin A induces apoptosis in human melanoma cell lines overexpressing the NK-1 receptor. Peptides, 2014, 55, 1-12.	1.2	8
54	Involvement of substance P and the NK-1 receptor in human pathology. Amino Acids, 2014, 46, 1727-1750.	1.2	174

#	Article	IF	CITATIONS
55	Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts. International Journal of Oncology, 2014, 44, 137-146.	1.4	47
56	The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer. International Journal of Oncology, 2014, 45, 1658-1672.	1.4	61
57	Cancer progression and substance P. Histology and Histopathology, 2014, 29, 881-90.	0.5	38
58	Involvement of substance P and the NK-1 receptor in pancreatic cancer. World Journal of Gastroenterology, 2014, 20, 2321.	1.4	35
59	Involvement of substance P and the NK-1 receptor in cancer progression. Peptides, 2013, 48, 1-9.	1.2	125
60	Mapping of alpha-neo-endorphin- and neurokinin B-immunoreactivity in the human brainstem. Brain Structure and Function, 2013, 218, 131-149.	1.2	12
61	Distribution of methionine-enkephalin in the minipig brainstem. Journal of Chemical Neuroanatomy, 2013, 50-51, 1-10.	1.0	5
62	GEMSP exerts a myelin-protecting role in the rat optic nerve. Neurological Research, 2013, 35, 903-911.	0.6	4
63	Safety of neurokinin-1 receptor antagonists. Expert Opinion on Drug Safety, 2013, 12, 673-685.	1.0	42
64	Immunolocalization of substance P and NK-1 receptor in hofbauer cells in human normal placenta. Microscopy Research and Technique, 2013, 76, 1310-1313.	1.2	7
65	Classical Neurotransmitters and Neuropeptides Involved in Schizophrenia: How to Choose the Appropriate Antipsychotic Drug?. Current Drug Therapy, 2013, 8, 132-143.	0.2	6
66	GEMSP: A New Therapeutic Approach to Multiple Sclerosis. Central Nervous System Agents in Medicinal Chemistry, 2012, 12, 173-181.	0.5	8
67	NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011. Expert Opinion on Therapeutic Patents, 2012, 22, 735-746.	2.4	23
68	The substance P/neurokinin-1 receptor system in lung cancer: Focus on the antitumor action of neurokinin-1 receptor antagonists. Peptides, 2012, 38, 318-325.	1.2	61
69	The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines. Investigational New Drugs, 2012, 30, 529-540.	1.2	39
70	Frontiers in Vitamin Research: New Antibodies, New Data. Scientific World Journal, The, 2011, 11, 1226-1242.	0.8	7
71	The NK-1 Receptor: A New Target in Cancer Therapy. Current Drug Targets, 2011, 12, 909-921.	1.0	76
72	NK-1 as a melanoma target. Expert Opinion on Therapeutic Targets, 2011, 15, 889-897.	1.5	14

#	Article	IF	CITATIONS
73	New drug therapies for multiple sclerosis. Current Opinion in Neurology, 2010, 23, 287-292.	1.8	17
74	Paravertebral anesthesia: how substance P and the NK-1 receptor could be involved in regional block and breast cancer recurrence. Breast Cancer Research and Treatment, 2010, 122, 601-603.	1.1	20
75	The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines. Laboratory Investigation, 2010, 90, 1259-1269.	1.7	84
76	The NK-1 Receptor Antagonist L-732,138 Induces Apoptosis and Counteracts Substance P-Related Mitogenesis in Human Melanoma Cell Lines. Cancers, 2010, 2, 611-623.	1.7	17
77	Classical Neurotransmitters and Neuropeptides Involved in Major Depression: a Review. International Journal of Neuroscience, 2010, 120, 455-470.	0.8	78
78	The broad-spectrum antitumor action of cyclosporin A is due to its tachykinin receptor antagonist pharmacological profile. Peptides, 2010, 31, 1643-1648.	1.2	12
79	Endotherapia. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2010, 9, 197-211.	1.1	4
80	Neurokinin-1 receptor: a new promising target in the treatment of cancer. Discovery Medicine, 2010, 10, 305-13.	0.5	28
81	Endotherapia: a new frontier in the treatment of multiple sclerosis and other chronic diseases. Discovery Medicine, 2010, 10, 443-51.	0.5	9
82	A New Drug Candidate (GEMSP) for Multiple Sclerosis. Current Medicinal Chemistry, 2009, 16, 3203-3214.	1.2	13
83	Circulating antibodies directed against "polycyclic aromatic hydrocarbon-like―structures in the sera of cancer patients. Cancer Epidemiology, 2009, 33, 3-8.	0.8	7
84	Mapping of CGRP in the alpaca (Lama pacos) brainstem. Journal of Chemical Neuroanatomy, 2008, 35, 346-355.	1.0	21
85	The NK-1 Receptor Is Expressed in Human Primary Gastric and Colon Adenocarcinomas and Is Involved in the Antitumor Action of L-733,060 and the Mitogenic Action of Substance P on Human Gastrointestinal Cancer Cell Lines. Tumor Biology, 2008, 29, 245-254.	0.8	86
86	Neurokinin-1 Receptors Located in Human Retinoblastoma Cell Lines: Antitumor Action of Its Antagonist, L-732,138. , 2007, 48, 2775.		55
87	The NK-1 Receptor is Involved in the Antitumoural Action of L-733,060 and in the Mitogenic Action of Substance P on Human Pancreatic Cancer Cell Lines. Letters in Drug Design and Discovery, 2006, 3, 323-329.	0.4	32
88	Antitumoral Action of the Neurokinin-1-Receptor Antagonist L-733,060 and Mitogenic Action of Substance P on Human Retinoblastoma Cell Lines. , 2005, 46, 2567.		56
89	Intracisternal galanin/angiotensin II interactions in central cardiovascular control. Regulatory Peptides, 2005, 127, 133-140.	1.9	10
90	Mapping of neurokinin-like immunoreactivity in the human brainstem. BMC Neuroscience, 2003, 4, 3.	0.8	37

#	Article	IF	CITATIONS
91	Angiotensin II modulates the cardiovascular responses to microinjection of NPY Y1 and NPY Y2 receptor agonists into the nucleus tractus solitarii of the rat. Brain Research, 2003, 983, 193-200.	1.1	9
92	Propranolol blocks the tachycardia induced by galanin (1–15) but not by galanin (1–29). Regulatory Peptides, 2002, 107, 29-36.	1.9	9
93	The galanin receptor antagonist M40 blocks the central cardiovascular actions of the galanin N-terminal fragment (1–15). European Journal of Pharmacology, 2000, 399, 197-203.	1.7	17
94	Distribution of gastrin-releasing peptide/bombesin-like immunoreactivity in the rainbow trout brain. Peptides, 1994, 15, 1027-1032.	1.2	5
95	Neuropeptides and monoamines in the carp (Cyprinus carpio) pretectum: An immunocytochemical study. Tissue and Cell, 1993, 25, 549-561.	1.0	5
96	Coexistence of c-Fos and glucocorticoid receptor immunoreactivities in the CRF immunoreactive neurons of the paraventricular hypothalamic nucleus of the rat after acute immobilization stress. Neuroscience Letters, 1993, 149, 149-152.	1.0	63
97	Neuropeptides and monoamines in the torus semicircularis of the carp (cyprinus carpio). Brain Research Bulletin, 1992, 29, 529-539.	1.4	11
98	Neuropeptides in the torus semicircularis of the carp (Cyprinus carpio). Brain Research Bulletin, 1992, 28, 593-598.	1.4	2
99	Immunocytochemical study of Met-enkephalin-like cell bodies in the cat hypothalamus. Neuroscience Research, 1988, 5, 353-360.	1.0	14
100	Immunocytochemical study of enkephalin-like cell bodies in the thalamus of the cat. Brain Research, 1986, 377, 355-361.	1.1	36